Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics files an amendment to its annual report to add detailed Part III disclosures on governance, executive pay, ownership and related-party transactions. The update does not change financial statements and instead refreshes information on directors, board committees and leadership roles, including CEO Jeet Mahal and Executive Chairperson Tom Wiggans.
The filing highlights 2025 compensation for senior executives, with Jeet Mahal earning a $498,000 salary, a $112,050 bonus and $679,549 in option awards, and CFO Herb Cross receiving similar pay levels. It also describes equity incentive plans, director retainers and options, severance and change-in-control protections, an insider trading policy that bans hedging and pledging, and a Nasdaq-compliant clawback policy for erroneously awarded incentive compensation.
Jasper Therapeutics reported its fourth quarter and full-year 2025 results and provided a corporate update focused on briquilimab, its antibody therapy for mast cell–driven diseases such as chronic urticaria and asthma. For 2025, operating expenses were $83.9 million, driven by $63.1 million in research and development and $20.8 million in general and administrative costs. Net loss for 2025 was $75.8 million compared with $71.3 million in 2024, reflecting continued investment in clinical programs. As of December 31, 2025, Jasper held $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier, and reported total assets of $35.8 million and stockholders’ equity of $4.2 million. The company plans to begin enrolling patients in the Phase 2b portion of a planned Phase 2b/3 chronic spontaneous urticaria study in the second half of 2026, pending capital availability.
Jasper Therapeutics, Inc. files its annual report outlining progress on briquilimab, a monoclonal antibody targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. The company highlights positive early-stage clinical data, a shift of resources away from stem cell transplant uses, and a strategy to build a focused mast cell therapeutics franchise.
Jasper holds worldwide rights to briquilimab under exclusive licenses from Amgen and Stanford, supported by patent families expected to expire in 2027 with newer applications potentially extending protection into the 2040s. The report also details regulatory pathways, manufacturing via Lonza, competitive landscape, and substantial ongoing funding needs with a history of operating losses and going-concern risk.
Jasper Therapeutics, Inc. reported Schedule 13G filings showing shared voting and dispositive power by several Millennium-related entities and an affiliate. Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 1,624,076 shares (5.8%).
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report shared voting and dispositive power over 1,629,013 shares (5.8% each). The filings include a Joint Filing Agreement dated 02/24/2026.
Jasper Therapeutics received an Amendment No. 4 to a Schedule 13D from a group of Carlyle- and Abingworth-affiliated entities updating their ownership in its voting common stock. The group reports beneficial ownership of 1,088,310 shares of common stock, representing 3.8% of the class, based on 27,984,039 shares outstanding as of November 6, 2025. The filing notes that, as of this amendment, the reporting persons have ceased to be beneficial owners of more than five percent of Jasper’s outstanding common stock and that they have not effected any transactions in the stock during the past 60 days. Voting and dispositive power over these shares is shared among the affiliated investment entities.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 1,764,848 shares of Jasper Therapeutics voting common stock, representing 6.3% of the class. They have shared voting and shared dispositive power over all of these shares, with no sole authority.
The firms state that the securities were acquired and are held in the ordinary course of business and not to change or influence control of Jasper Therapeutics. A joint filing agreement confirms that both entities are reporting together, with signatures provided by an attorney-in-fact dated January 6, 2026.
Morgan Stanley filed a Schedule 13G reporting a significant ownership position in Jasper Therapeutics, Inc. voting common stock. Morgan Stanley reports beneficial ownership of 1,969,785 shares, representing 7.0% of the class, with shared voting and shared dispositive power over these shares.
Affiliated entity Morgan Stanley Capital Services LLC reports beneficial ownership of 1,903,420 shares, or 6.8% of the class, also with shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics CEO and President Jeetinder Singh Mahal received a stock option covering 500,000 shares of voting common stock on February 6, 2026. The option has an exercise price of $1.35 per share and expires on February 6, 2036.
According to the vesting terms, one quarter of the option vests on February 6, 2027, with the remaining three quarters vesting in equal monthly installments over the following 36 months, conditioned on continued service with the company.
A shareholder group associated with Anders Hove filed an amended Schedule 13G reporting beneficial ownership of 1,486,492 shares of Jasper Therapeutics, Inc. common stock, equal to 5.3% of the class. This ownership is held through investment entities including Acorn Bioventures, L.P. and Acorn Bioventures 2, L.P., with related general partners Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC. The percentages are based on 27,984,039 shares of common stock outstanding as of November 6, 2025. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics, Inc. reported that it has released a press release with positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria, along with data from an open-label extension study in chronic spontaneous and chronic inducible urticaria. The company is also hosting a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026 to present these updated BEACON and open-label extension results. The press release and the related investor presentation are provided as exhibits to this report.